Catalog name Description price
R-C-435 BMS777607 Bms-777607 is a met related inhibitor, which acts on c-Met,Axl,Ron and TYRO3 with IC50 of 3.9 nm,1.1 nm,1.8 nm and 4.3 nm respectively in cell-free assay.The selectivity of bms-777607 on met related targets is 40 times higher than that on Lck,VEGFR-2 and TrkA/B,and more than 500 times higher than that on other receptor and non receptor kinases. price>
R-C-438 Telatinib (BAY 57-9352) Telatinib has low affinity for Raf kinase pathway,epidermal growth factor receptor family,fibroblast growth factor receptor(FGFR) family or Tie-2 receptor.Tiratinib is metabolized by a variety of cytochrome P450 (CYP) subtypes, including CYP3A4/3A5,cyp2c8, CYP2C9 and CYP2C19,as well as uridine diphosphate glucuronosyltransferase 1A4 (ugt1a4).The formation of N-glucuronide is the main biotransformation pathway of tiratinib. price>
R-C-439 gsk1904529A Gsk-1904529a is an IGF-1R inhibitor,which has broad application prospects in the treatment of igf-ir-dependent tumors.Gsk1904529a selectively inhibited IGF-IR and IR with IC50 of 27 and 25 nmol/L,respectively.Gsk1904529a blocks autophosphorylation and downstream signal transduction of receptor,leading to cell cycle arrest.It inhibits the proliferation of cell lines from solid and hematological malignancies.Multiple myeloma and Ewing sarcoma cell lines are the most sensitive. price>
R-C-442 Brivanib(bms-540215) Brivanib is an ATP-competitive inhibitor against human Flk-1(VEGFR-2)and mouse Flk-1 with IC50 of 25 nM and 89 nM,respectively.Brivanib also inhibits Flt-1 (VEGFR-1)and Flg (FGFR-1) with IC50 of 0.38 and 0.148 μM.Brivanib displays antitumor activities in H3396 xenograft.This compound completely inhibits the tumor growth,with TGI of 85% and 97%, respectively. price>
R-C-443 Brivanib alaninate(BMS-582664) Brivanib Alaninate is the alaninate salt of a vascular endothelial growth factor receptor 2(VEGFR2) inhibitor with potential antineoplastic activity.Brivanib strongly binds to and inhibits VEGFR2,a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells;inhibition of VEGFR2 may result in inhibition of tumor angiogenesis,inhibition of tumor cell growth,and tumor regression. price>
R-C-445 Linifanib (ABT-869) Linifanib(ABT-869) is a novel,potent ATP-competitive VEGFR/PDGFR inhibitor for KDR(IC50:4 nM),CSF-1R (IC50:3 nM),Flt-1/3(IC50:3/4 nM)and PDGFRβ(IC50:66 nM).Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases,such as FMS-related tyrosine kinase receptor-3 (FLT3). price>
R-C-470 PHA665752 CAS:477575-56-7 PHA-665752 is a selective,ATP-competitive,and active-site inhibitor of the catalytic activity of c-Met kinase (Ki=4 nM;IC50=9 nM).PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases.PHA-665752 induces apoptosis and cell cycle arrest,and exhibits cytoreductive antitumor activity. price>
R-C-475 AST-1306 CAS:897383-62-9 AST-1306,a novel anilino-quinazoline compound,inhibits the enzymatic activities of wild-type epidermal growth factor receptor(EGFR)and ErbB2 as well as EGFR resistant mutant in both cell-free and cell-based systems.It is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM,also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases. price>
R-C-478 Foretinib(XL880) CAS:849217-64-7 Foretinib(GSK1363089,EXEL-2880,XL-880) is an ATP-competitive inhibitor of HGFR and VEGFR,mostly for Met (c-Met)and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays.Less potent against Ron,Flt-1/3/4,Kit (c-Kit), PDGFRα/β and Tie-2,and little activity to FGFR1 and EGFR. price>
R-C-479 Glesatinib(MGCD265) CAS:875337-44-3 MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs,including the c-Met receptor (HGFR);the Tek/Tie-2 receptor;VEGFR types 1,2,and 3;and MST1R. price>